Seres Therapeutics Inc (MCRB)

Currency in USD
13.0900
+0.7000(+5.65%)
Closed·
After Hours
12.8300-0.2600(-1.99%)
·
MCRB Scorecard
Full Analysis
Quickly burning through cash
Earnings results expected in 12 days
Fair Value
Day's Range
12.500013.2000
52 wk Range
6.530029.4000
Key Statistics
Prev. Close
12.39
Open
13
Day's Range
12.5-13.2
52 wk Range
6.53-29.4
Volume
168.98K
Average Volume (3m)
115.36K
1-Year Change
-49.63%
Book Value / Share
5.79
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MCRB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
13.3333
Upside
+1.86%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Seres Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy

Seres Therapeutics Inc Company Profile

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Seres Therapeutics Inc Earnings Call Summary for Q1/2025

  • Net income surged to $32.7M in Q1 2025, reversing a $32.9M loss, driven by a $50M payment from Nestle
  • Stock closed down 7.37% at $8.55 post-earnings, but rebounded 8.65% to $9.29 in premarket trading
  • R&D and G&A expenses decreased year-over-year, indicating effective cost management efforts
  • SER-155 advancing with FDA breakthrough therapy designation; Phase II study protocol submission imminent
  • Company exploring partnerships to expand in inflammatory and immune disease markets
Last Updated: 07/05/2025, 14:24
Read Full Transcript

Compare MCRB to Peers and Sector

Metrics to compare
MCRB
Peers
Sector
Relationship
P/E Ratio
−1.9x−5.1x−0.5x
PEG Ratio
−0.010.020.00
Price/Book
2.3x3.5x2.6x
Price / LTM Sales
-218.6x3.2x
Upside (Analyst Target)
13.0%132.6%42.7%
Fair Value Upside
Unlock6.3%5.8%Unlock

Analyst Ratings

2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 13.3333
(+1.86% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
3.75 / 0.0651
Revenue / Forecast
-- / 20.00M
EPS Revisions
Last 90 days

MCRB Income Statement

People Also Watch

5.14
SANA
+5.54%
6.47
FHTX
+2.05%
47.850
SMR
+7.67%
40.530
ARQQ
+2.97%
126.04
CRWV
-2.87%

FAQ

What Stock Exchange Does Seres Therapeutics Inc Trade On?

Seres Therapeutics Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Seres Therapeutics Inc?

The stock symbol for Seres Therapeutics Inc is "MCRB."

What Is the Seres Therapeutics Inc Market Cap?

As of today, Seres Therapeutics Inc market cap is 113.13M.

What Is Seres Therapeutics Inc's Earnings Per Share (TTM)?

The Seres Therapeutics Inc EPS (TTM) is -7.41.

When Is the Next Seres Therapeutics Inc Earnings Date?

Seres Therapeutics Inc will release its next earnings report on 04 Aug 2025.

From a Technical Analysis Perspective, Is MCRB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Seres Therapeutics Inc Stock Split?

Seres Therapeutics Inc has split 1 times.

How Many Employees Does Seres Therapeutics Inc Have?

Seres Therapeutics Inc has 103 employees.

What is the current trading status of Seres Therapeutics Inc (MCRB)?

As of 23 Jul 2025, Seres Therapeutics Inc (MCRB) is trading at a price of 13.09, with a previous close of 12.39. The stock has fluctuated within a day range of 12.50 to 13.20, while its 52-week range spans from 6.53 to 29.40.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.